Asthma is an inflammatory disease which affects millions of people worldwide. 
Therefore, it is necessary to search for new sources of therapies for the 
treatment of these patients in order to improve their quality of life. From 
content analysis of literature of new therapeutic targets, there are various 
targets and drugs reported to be promising for the treatment of asthma. 
Interleukins involved in inflammatory processes are often presented as candidate 
targets for new drugs. The action of such therapeutics would not only affect 
interleukins, but also their receptors. Small molecules (e.g. ligustrazine and 
SP600125) and large molecule antibodies (e.g. lebrikizumab, benralizumab, 
dupilumab) are being considered as novel agents for the pharmacotherapy of 
asthma. Therefore, through this research, we can see advances in the search for 
new targets and promising drugs to treat asthma. It is expected that these new 
drug candidates will eventually be approved and marketed so that asthma patients 
can use them to enhance their quality of life.